Global Post-Traumatic Stress Disorder Therapeutics Market

Post-Traumatic Stress Disorder Therapeutics Comprehensive Study by End-Users (Male, Female, Children), Drug Class (Antidepressants, Anti-anxiety Drugs, Other Drug Class) Players and Region - Global Market Outlook to 2030

Post-Traumatic Stress Disorder Therapeutics Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Post-Traumatic Stress Disorder Therapeutics
Post-traumatic stress disorder (PTSD) therapeutics contain drugs which are used in the treatment of post-traumatic stress disorder. Post-traumatic stress disorder (PTSD) is a psychological condition which occurs in persons of any age & gender. Its indications can show up instantly after a traumatic experience or with the course of time. PTSD is one of the most common psychological disorders, affecting many million adults around the globe. Its first line of treatments contains counseling & psychotherapy. The population at risk contains veterans as well as soldiers. Most common drugs that are usually prescribed are Elavil by AstraZeneca, Zoloft by Pfizer, & Paxil by GlaxoSmithKline. Rising prevalence of post-traumatic stress disorder is likely to impel the growth of global Post-traumatic stress disorder therapeutics market.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia-Pacific
UnitValue (USD Million)
CAGR4.1%


Global Post-Traumatic Stress Disorder Therapeutics is a fragmented market due to the presence of various players. The players are focusing on investing more in Launching Products. These will enhance their market presence. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Analyst at AMA Research estimates that United Kingdom and United States Players will contribute the maximum growth to Global Post-Traumatic Stress Disorder Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline Plc. (United Kingdom), Pfizer Inc. (United Sates), Neurocrine Biosciences (United Sates), Novartis International AG (Switzerland), Azevan Pharmaceuticals (United Sates), AstraZeneca plc. (United Kingdom), Eli Lilly and Company (United Sates) and H. Lundbeck A/S (Denmark) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Post-Traumatic Stress Disorder Therapeutics market by and Region.



On the basis of geography, the market of Post-Traumatic Stress Disorder Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by End-Users, the sub-segment i.e. Male will boost the Post-Traumatic Stress Disorder Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Antidepressants will boost the Post-Traumatic Stress Disorder Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emerging Therapies for PTSD Treatment

Market Growth Drivers:
Rising Prevalence of Post-Traumatic Stress Disorder, Growing Initiatives by Public and Private Organizations and Increasing Events of Violence and Wars

Challenges:
Unmet Requirement for Existing Therapies

Restraints:
Lack of Timely Diagnosis and Access to Care and Risk of Side Effects

Opportunities:
Promising Pipeline Candidates and Untapped Opportunities in Emerging Markets

Market Leaders and their expansionary development strategies
In July 2023, Psy Therapeutics Partners with MAPS for MDMA-Assisted PTSD Therapy. This collaboration aimed to expand access to MDMA-assisted therapy, a promising new treatment approach for PTSD, through clinical trials and potential future commercialization.
In June 2023, Xywav (moesifin-afimicetin) this medication received FDA approval for treating adults with insomnia associated with PTSD. Xywav's rapid onset and short duration of action addressed a critical need for improved sleep management in PTSD patients.
The guideline describes the critical decision points in the management of post-traumatic stress disorder and acute stress reactions and provides clear and comprehensive evidence-based recommendations for practitioners across the DoD and VA healthcare systems, incorporating current information and practices. The goal of the guideline is to improve patient outcomes and local management of patients who have one of these diagnoses.

Key Target Audience
Post-Traumatic Stress Disorder Therapeutics Manufacturers, Raw Materials Suppliers, Government and Research Organizations, Industry Associations, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By End-Users
  • Male
  • Female
  • Children

By Drug Class
  • Antidepressants
  • Anti-anxiety Drugs
  • Other Drug Class

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Post-Traumatic Stress Disorder
      • 3.2.2. Growing Initiatives by Public and Private Organizations
      • 3.2.3. Increasing Events of Violence and Wars
    • 3.3. Market Challenges
      • 3.3.1. Unmet Requirement for Existing Therapies
    • 3.4. Market Trends
      • 3.4.1. Emerging Therapies for PTSD Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Post-Traumatic Stress Disorder Therapeutics, by End-Users, Drug Class and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Post-Traumatic Stress Disorder Therapeutics (Value)
      • 5.2.1. Global Post-Traumatic Stress Disorder Therapeutics by: End-Users (Value)
        • 5.2.1.1. Male
        • 5.2.1.2. Female
        • 5.2.1.3. Children
      • 5.2.2. Global Post-Traumatic Stress Disorder Therapeutics by: Drug Class (Value)
        • 5.2.2.1. Antidepressants
        • 5.2.2.2. Anti-anxiety Drugs
        • 5.2.2.3. Other Drug Class
      • 5.2.3. Global Post-Traumatic Stress Disorder Therapeutics Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Post-Traumatic Stress Disorder Therapeutics (Volume)
      • 5.3.1. Global Post-Traumatic Stress Disorder Therapeutics by: End-Users (Volume)
        • 5.3.1.1. Male
        • 5.3.1.2. Female
        • 5.3.1.3. Children
      • 5.3.2. Global Post-Traumatic Stress Disorder Therapeutics by: Drug Class (Volume)
        • 5.3.2.1. Antidepressants
        • 5.3.2.2. Anti-anxiety Drugs
        • 5.3.2.3. Other Drug Class
      • 5.3.3. Global Post-Traumatic Stress Disorder Therapeutics Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Post-Traumatic Stress Disorder Therapeutics (Price)
  • 6. Post-Traumatic Stress Disorder Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United Sates)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Neurocrine Biosciences (United Sates)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis International AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Azevan Pharmaceuticals (United Sates)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca plc. (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly and Company (United Sates)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. H. Lundbeck A/S (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Post-Traumatic Stress Disorder Therapeutics Sale, by End-Users, Drug Class and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Post-Traumatic Stress Disorder Therapeutics (Value)
      • 7.2.1. Global Post-Traumatic Stress Disorder Therapeutics by: End-Users (Value)
        • 7.2.1.1. Male
        • 7.2.1.2. Female
        • 7.2.1.3. Children
      • 7.2.2. Global Post-Traumatic Stress Disorder Therapeutics by: Drug Class (Value)
        • 7.2.2.1. Antidepressants
        • 7.2.2.2. Anti-anxiety Drugs
        • 7.2.2.3. Other Drug Class
      • 7.2.3. Global Post-Traumatic Stress Disorder Therapeutics Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Post-Traumatic Stress Disorder Therapeutics (Volume)
      • 7.3.1. Global Post-Traumatic Stress Disorder Therapeutics by: End-Users (Volume)
        • 7.3.1.1. Male
        • 7.3.1.2. Female
        • 7.3.1.3. Children
      • 7.3.2. Global Post-Traumatic Stress Disorder Therapeutics by: Drug Class (Volume)
        • 7.3.2.1. Antidepressants
        • 7.3.2.2. Anti-anxiety Drugs
        • 7.3.2.3. Other Drug Class
      • 7.3.3. Global Post-Traumatic Stress Disorder Therapeutics Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Post-Traumatic Stress Disorder Therapeutics (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Post-Traumatic Stress Disorder Therapeutics: by End-Users(USD Million)
  • Table 2. Post-Traumatic Stress Disorder Therapeutics Male , by Region USD Million (2018-2023)
  • Table 3. Post-Traumatic Stress Disorder Therapeutics Female , by Region USD Million (2018-2023)
  • Table 4. Post-Traumatic Stress Disorder Therapeutics Children , by Region USD Million (2018-2023)
  • Table 5. Post-Traumatic Stress Disorder Therapeutics: by Drug Class(USD Million)
  • Table 6. Post-Traumatic Stress Disorder Therapeutics Antidepressants , by Region USD Million (2018-2023)
  • Table 7. Post-Traumatic Stress Disorder Therapeutics Anti-anxiety Drugs , by Region USD Million (2018-2023)
  • Table 8. Post-Traumatic Stress Disorder Therapeutics Other Drug Class , by Region USD Million (2018-2023)
  • Table 9. South America Post-Traumatic Stress Disorder Therapeutics, by Country USD Million (2018-2023)
  • Table 10. South America Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 11. South America Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 12. Brazil Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 13. Brazil Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 14. Argentina Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 15. Argentina Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 16. Rest of South America Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 17. Rest of South America Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 18. Asia Pacific Post-Traumatic Stress Disorder Therapeutics, by Country USD Million (2018-2023)
  • Table 19. Asia Pacific Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 20. Asia Pacific Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 21. China Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 22. China Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 23. Japan Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 24. Japan Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 25. India Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 26. India Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 27. South Korea Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 28. South Korea Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 29. Taiwan Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 30. Taiwan Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 31. Australia Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 32. Australia Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 33. Rest of Asia-Pacific Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 34. Rest of Asia-Pacific Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 35. Europe Post-Traumatic Stress Disorder Therapeutics, by Country USD Million (2018-2023)
  • Table 36. Europe Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 37. Europe Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 38. Germany Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 39. Germany Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 40. France Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 41. France Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 42. Italy Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 43. Italy Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 44. United Kingdom Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 45. United Kingdom Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 46. Netherlands Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 47. Netherlands Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 48. Rest of Europe Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 49. Rest of Europe Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 50. MEA Post-Traumatic Stress Disorder Therapeutics, by Country USD Million (2018-2023)
  • Table 51. MEA Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 52. MEA Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 53. Middle East Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 54. Middle East Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 55. Africa Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 56. Africa Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 57. North America Post-Traumatic Stress Disorder Therapeutics, by Country USD Million (2018-2023)
  • Table 58. North America Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 59. North America Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 60. United States Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 61. United States Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 62. Canada Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 63. Canada Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 64. Mexico Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2018-2023)
  • Table 65. Mexico Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 66. Post-Traumatic Stress Disorder Therapeutics Sales: by End-Users(K Units)
  • Table 67. Post-Traumatic Stress Disorder Therapeutics Sales Male , by Region K Units (2018-2023)
  • Table 68. Post-Traumatic Stress Disorder Therapeutics Sales Female , by Region K Units (2018-2023)
  • Table 69. Post-Traumatic Stress Disorder Therapeutics Sales Children , by Region K Units (2018-2023)
  • Table 70. Post-Traumatic Stress Disorder Therapeutics Sales: by Drug Class(K Units)
  • Table 71. Post-Traumatic Stress Disorder Therapeutics Sales Antidepressants , by Region K Units (2018-2023)
  • Table 72. Post-Traumatic Stress Disorder Therapeutics Sales Anti-anxiety Drugs , by Region K Units (2018-2023)
  • Table 73. Post-Traumatic Stress Disorder Therapeutics Sales Other Drug Class , by Region K Units (2018-2023)
  • Table 74. South America Post-Traumatic Stress Disorder Therapeutics Sales, by Country K Units (2018-2023)
  • Table 75. South America Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 76. South America Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 77. Brazil Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 78. Brazil Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 79. Argentina Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 80. Argentina Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 81. Rest of South America Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 82. Rest of South America Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 83. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Sales, by Country K Units (2018-2023)
  • Table 84. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 85. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 86. China Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 87. China Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 88. Japan Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 89. Japan Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 90. India Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 91. India Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 92. South Korea Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 93. South Korea Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 94. Taiwan Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 95. Taiwan Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 96. Australia Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 97. Australia Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 98. Rest of Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 99. Rest of Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 100. Europe Post-Traumatic Stress Disorder Therapeutics Sales, by Country K Units (2018-2023)
  • Table 101. Europe Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 102. Europe Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 103. Germany Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 104. Germany Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 105. France Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 106. France Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 107. Italy Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 108. Italy Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 109. United Kingdom Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 110. United Kingdom Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 111. Netherlands Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 112. Netherlands Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 113. Rest of Europe Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 114. Rest of Europe Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 115. MEA Post-Traumatic Stress Disorder Therapeutics Sales, by Country K Units (2018-2023)
  • Table 116. MEA Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 117. MEA Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 118. Middle East Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 119. Middle East Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 120. Africa Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 121. Africa Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 122. North America Post-Traumatic Stress Disorder Therapeutics Sales, by Country K Units (2018-2023)
  • Table 123. North America Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 124. North America Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 125. United States Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 126. United States Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 127. Canada Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 128. Canada Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 129. Mexico Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2018-2023)
  • Table 130. Mexico Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2018-2023)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Post-Traumatic Stress Disorder Therapeutics: by End-Users(USD Million)
  • Table 140. Post-Traumatic Stress Disorder Therapeutics Male , by Region USD Million (2025-2030)
  • Table 141. Post-Traumatic Stress Disorder Therapeutics Female , by Region USD Million (2025-2030)
  • Table 142. Post-Traumatic Stress Disorder Therapeutics Children , by Region USD Million (2025-2030)
  • Table 143. Post-Traumatic Stress Disorder Therapeutics: by Drug Class(USD Million)
  • Table 144. Post-Traumatic Stress Disorder Therapeutics Antidepressants , by Region USD Million (2025-2030)
  • Table 145. Post-Traumatic Stress Disorder Therapeutics Anti-anxiety Drugs , by Region USD Million (2025-2030)
  • Table 146. Post-Traumatic Stress Disorder Therapeutics Other Drug Class , by Region USD Million (2025-2030)
  • Table 147. South America Post-Traumatic Stress Disorder Therapeutics, by Country USD Million (2025-2030)
  • Table 148. South America Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 149. South America Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 150. Brazil Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 151. Brazil Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 152. Argentina Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 153. Argentina Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 154. Rest of South America Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 155. Rest of South America Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 156. Asia Pacific Post-Traumatic Stress Disorder Therapeutics, by Country USD Million (2025-2030)
  • Table 157. Asia Pacific Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 158. Asia Pacific Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 159. China Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 160. China Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 161. Japan Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 162. Japan Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 163. India Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 164. India Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 165. South Korea Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 166. South Korea Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 167. Taiwan Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 168. Taiwan Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 169. Australia Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 170. Australia Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 171. Rest of Asia-Pacific Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 172. Rest of Asia-Pacific Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 173. Europe Post-Traumatic Stress Disorder Therapeutics, by Country USD Million (2025-2030)
  • Table 174. Europe Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 175. Europe Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 176. Germany Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 177. Germany Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 178. France Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 179. France Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 180. Italy Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 181. Italy Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 182. United Kingdom Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 183. United Kingdom Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 184. Netherlands Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 185. Netherlands Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 186. Rest of Europe Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 187. Rest of Europe Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 188. MEA Post-Traumatic Stress Disorder Therapeutics, by Country USD Million (2025-2030)
  • Table 189. MEA Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 190. MEA Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 191. Middle East Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 192. Middle East Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 193. Africa Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 194. Africa Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 195. North America Post-Traumatic Stress Disorder Therapeutics, by Country USD Million (2025-2030)
  • Table 196. North America Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 197. North America Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 198. United States Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 199. United States Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 200. Canada Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 201. Canada Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 202. Mexico Post-Traumatic Stress Disorder Therapeutics, by End-Users USD Million (2025-2030)
  • Table 203. Mexico Post-Traumatic Stress Disorder Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 204. Post-Traumatic Stress Disorder Therapeutics Sales: by End-Users(K Units)
  • Table 205. Post-Traumatic Stress Disorder Therapeutics Sales Male , by Region K Units (2025-2030)
  • Table 206. Post-Traumatic Stress Disorder Therapeutics Sales Female , by Region K Units (2025-2030)
  • Table 207. Post-Traumatic Stress Disorder Therapeutics Sales Children , by Region K Units (2025-2030)
  • Table 208. Post-Traumatic Stress Disorder Therapeutics Sales: by Drug Class(K Units)
  • Table 209. Post-Traumatic Stress Disorder Therapeutics Sales Antidepressants , by Region K Units (2025-2030)
  • Table 210. Post-Traumatic Stress Disorder Therapeutics Sales Anti-anxiety Drugs , by Region K Units (2025-2030)
  • Table 211. Post-Traumatic Stress Disorder Therapeutics Sales Other Drug Class , by Region K Units (2025-2030)
  • Table 212. South America Post-Traumatic Stress Disorder Therapeutics Sales, by Country K Units (2025-2030)
  • Table 213. South America Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 214. South America Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 215. Brazil Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 216. Brazil Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 217. Argentina Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 218. Argentina Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 219. Rest of South America Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 220. Rest of South America Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 221. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Sales, by Country K Units (2025-2030)
  • Table 222. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 223. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 224. China Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 225. China Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 226. Japan Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 227. Japan Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 228. India Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 229. India Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 230. South Korea Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 231. South Korea Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 232. Taiwan Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 233. Taiwan Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 234. Australia Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 235. Australia Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 236. Rest of Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 237. Rest of Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 238. Europe Post-Traumatic Stress Disorder Therapeutics Sales, by Country K Units (2025-2030)
  • Table 239. Europe Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 240. Europe Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 241. Germany Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 242. Germany Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 243. France Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 244. France Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 245. Italy Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 246. Italy Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 247. United Kingdom Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 248. United Kingdom Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 249. Netherlands Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 250. Netherlands Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 251. Rest of Europe Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 252. Rest of Europe Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 253. MEA Post-Traumatic Stress Disorder Therapeutics Sales, by Country K Units (2025-2030)
  • Table 254. MEA Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 255. MEA Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 256. Middle East Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 257. Middle East Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 258. Africa Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 259. Africa Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 260. North America Post-Traumatic Stress Disorder Therapeutics Sales, by Country K Units (2025-2030)
  • Table 261. North America Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 262. North America Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 263. United States Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 264. United States Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 265. Canada Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 266. Canada Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 267. Mexico Post-Traumatic Stress Disorder Therapeutics Sales, by End-Users K Units (2025-2030)
  • Table 268. Mexico Post-Traumatic Stress Disorder Therapeutics Sales, by Drug Class K Units (2025-2030)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Post-Traumatic Stress Disorder Therapeutics: by End-Users USD Million (2018-2023)
  • Figure 5. Global Post-Traumatic Stress Disorder Therapeutics: by Drug Class USD Million (2018-2023)
  • Figure 6. South America Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 7. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 8. Europe Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 9. MEA Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 10. North America Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 11. Global Post-Traumatic Stress Disorder Therapeutics: by End-Users K Units (2018-2023)
  • Figure 12. Global Post-Traumatic Stress Disorder Therapeutics: by Drug Class K Units (2018-2023)
  • Figure 13. South America Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 14. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 15. Europe Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 16. MEA Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 17. North America Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 18. Global Post-Traumatic Stress Disorder Therapeutics share by Players 2023 (%)
  • Figure 19. Global Post-Traumatic Stress Disorder Therapeutics share by Players (Top 3) 2023(%)
  • Figure 20. Global Post-Traumatic Stress Disorder Therapeutics share by Players (Top 5) 2023(%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 24. Pfizer Inc. (United Sates) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer Inc. (United Sates) Revenue: by Geography 2023
  • Figure 26. Neurocrine Biosciences (United Sates) Revenue, Net Income and Gross profit
  • Figure 27. Neurocrine Biosciences (United Sates) Revenue: by Geography 2023
  • Figure 28. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 30. Azevan Pharmaceuticals (United Sates) Revenue, Net Income and Gross profit
  • Figure 31. Azevan Pharmaceuticals (United Sates) Revenue: by Geography 2023
  • Figure 32. AstraZeneca plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. AstraZeneca plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 34. Eli Lilly and Company (United Sates) Revenue, Net Income and Gross profit
  • Figure 35. Eli Lilly and Company (United Sates) Revenue: by Geography 2023
  • Figure 36. H. Lundbeck A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 37. H. Lundbeck A/S (Denmark) Revenue: by Geography 2023
  • Figure 38. Global Post-Traumatic Stress Disorder Therapeutics: by End-Users USD Million (2025-2030)
  • Figure 39. Global Post-Traumatic Stress Disorder Therapeutics: by Drug Class USD Million (2025-2030)
  • Figure 40. South America Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 41. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 42. Europe Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 43. MEA Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 44. North America Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 45. Global Post-Traumatic Stress Disorder Therapeutics: by End-Users K Units (2025-2030)
  • Figure 46. Global Post-Traumatic Stress Disorder Therapeutics: by Drug Class K Units (2025-2030)
  • Figure 47. South America Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 48. Asia Pacific Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 49. Europe Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 50. MEA Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
  • Figure 51. North America Post-Traumatic Stress Disorder Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline Plc. (United Kingdom)
  • Pfizer Inc. (United Sates)
  • Neurocrine Biosciences (United Sates)
  • Novartis International AG (Switzerland)
  • Azevan Pharmaceuticals (United Sates)
  • AstraZeneca plc. (United Kingdom)
  • Eli Lilly and Company (United Sates)
  • H. Lundbeck A/S (Denmark)
Select User Access Type

Key Highlights of Report


Jan 2024 145 Pages 60 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Post-Traumatic Stress Disorder Therapeutics Market Quantitative research analysis
Global Post-Traumatic Stress Disorder Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline Plc. (United Kingdom), Pfizer Inc. (United Sates), Neurocrine Biosciences (United Sates), Novartis International AG (Switzerland), Azevan Pharmaceuticals (United Sates), AstraZeneca plc. (United Kingdom), Eli Lilly and Company (United Sates) and H. Lundbeck A/S (Denmark) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Emerging Therapies for PTSD Treatment" is seen as one of major influencing trends for Post-Traumatic Stress Disorder Therapeutics Market during projected period 2023-2030.
The Post-Traumatic Stress Disorder Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Post-Traumatic Stress Disorder Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Thalassemia Comprehensive Study by Type (Alpha-Thalassemia, Beta Thalassemia), Application (Hospital, Clinic, Research Institute, Laboratories), Treatment Type (Blood Transfusions, Iron Chelation The...
$ 3650
Melanoma Therapeutics Comprehensive Study by Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generics), Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiat...
$ 3750
Appendix Cancer Treatment Comprehensive Study by Type (Neuroendocrine Tumors, Carcinomas, Mucinous Adenocarcinoma (low grade, high grade), Global Cell Carcinoids, Intestinal Type Adenocarcinoma, Sign...
$ 3750
Diabetes Therapeutics and Diagnostics Comprehensive Study by Type (Injectable (Insulin, Amylinomimetic), Oral (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl ...
$ 3750
Daptomycin Comprehensive Study by Type (350 mg lyophilized powder, 500 mg lyophilized powder), Application (Adult, Pediatric patients (1 to 17 years of age)), End -Users (Pharmaceuticals, Clinics, We...
$ 3500
Epistaxis Comprehensive Study by Type (Vasoconstrictors, Anesthetics, Antibiotic Ointments, Cauterizing Agents, Others), Application (Anterior Epistaxis, Posterior Epistaxis), Treatment (Medication, ...
$ 3650